47.71

0.44% 0.21

After Hours: 47.71

Sanofi Adr (SNY)

Overview News Price History Option Chain Why SNY Down? Discussions Forecast Dividend History

Sanofi Adr stock is traded at $47.71, with a volume of 2.41M. It is up +0.44% in the last 24 hours and down -0.15% over the past month. Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Previous Close:

$47.50

Open:

$46.92

24h Volume:

2.41M

Relative Volume:

1.16

Market Cap:

$119.62B

Revenue:

$53.04B

Net Income/Loss:

$4.93B

P/E Ratio:

15.03

EPS:

3.1735

Net Cash Flow:

$9.91B

1W Performance:

+1.94%

1M Performance:

-0.15%

6M Performance:

+1.84%

1Y Performance:

-1.04%

1-Day Range:

$46.89

$47.90

1-Week Range:

$45.80

$49.73

52-Week Range:

$45.22

$58.97

Sanofi Adr Stock (SNY) Company Profile

Name

Sanofi Adr

Sector

Healthcare (1176)

Industry

Drug Manufacturers - General (18)

Phone

Address

Employee

87,994

Twitter

@sanofi

Next Earnings Date

2024-10-25

Latest SEC Filings

SNY's Discussions on Twitter

Compare SNY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNY Sanofi Adr	47.71	119.62B	53.04B	4.93B	9.91B	1.9736
LLY Lilly Eli Co	767.76	690.46B	40.86B	8.37B	-2.28B	9.25
NVO Novo Nordisk Adr	85.00	377.54B	39.36B	13.79B	9.83B	3.086
JNJ Johnson Johnson	144.47	347.83B	87.70B	14.68B	19.03B	6.05
ABBV Abbvie Inc	175.58	310.27B	55.53B	5.12B	15.62B	2.88
MRK Merck Co Inc	98.05	248.03B	63.17B	12.15B	14.84B	4.77

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-26-24	Reiterated	Argus	Buy
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
Sep-20-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-03-19	Initiated	Bernstein	Outperform
Aug-14-19	Upgrade	UBS	Neutral → Buy
Dec-11-18	Upgrade	Jefferies	Hold → Buy
Nov-01-18	Upgrade	Barclays	Underweight → Equal Weight
Oct-09-18	Initiated	Guggenheim	Neutral
Sep-10-18	Upgrade	BofA/Merrill	Neutral → Buy
Aug-10-18	Upgrade	Citigroup	Neutral → Buy
Mar-23-18	Upgrade	Liberum	Hold → Buy
Jan-23-18	Downgrade	Barclays	Equal Weight → Underweight
Dec-06-17	Downgrade	BofA/Merrill	Buy → Neutral
Dec-01-17	Downgrade	Morgan Stanley	Overweight → Underweight
Nov-15-17	Upgrade	Barclays	Underweight → Equal Weight
Aug-30-17	Upgrade	HSBC Securities	Reduce → Hold